A Retrospective Study of Reirradiation for Patients with Locoregional Recurrent Head and Neck Cancer: A Single-Institution Experience
<span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">Aim: To assess the efficacy of reirradiation in locoregionally recurrent head and neck cancer (HNC) and </spa...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Kasr Al-Ainy Center of Clinical Oncology and Nuclear Medicine
2016-06-01
|
| Series: | Research in Oncology |
| Subjects: | |
| Online Access: | https://resoncol.journals.ekb.eg/article_587_c9dc1a19a6306d4d48666d1f41703538.pdf |
| _version_ | 1818776659857244160 |
|---|---|
| author | Dina Salem Ahmed Essa Azza Adel Ahmed Refaa |
| author_facet | Dina Salem Ahmed Essa Azza Adel Ahmed Refaa |
| author_sort | Dina Salem |
| collection | DOAJ |
| description | <span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">Aim: To assess the efficacy of reirradiation in locoregionally recurrent head and neck cancer (HNC) and </span></span><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">to describe results in our center in relation to other published data among similar group of patients. </span></span><br /> <span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">Methods: <span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">The medical records of 28 patients with HNC who received reirradiation with or without chemotherapy for loco-regional recurrence between 2005 and 2013 were reviewed. They were evaluated </span></span><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">for; toxicity profile, overall survival (OS) and progression free survival (PFS). </span></span></span></span><br /> <span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">Results: <span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">The median reirradiation dose was 50 Gy (range 40-60 Gy) and median radiation cumulative dose was 119 (range 113 -120). An overall response rate was seen in 36% of patients with only 3 patients showed complete response. The median OS was 9 months with 1-and 2-year survival rates being 34.1% </span></span><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">and 10.6%. The OS and PFS were significantly better in patients who were treated with chemotherapy </span></span><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">concomitant with radiation and received higher radiation dose. Grade 3 mucositis and skin reactions were seen in 24 % and 14% of patients, respectively. Conclusion: <span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">Reirradiation appears to be feasible in patients with recurrent HNC treated previously with </span></span><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">radiation. The benefit of concurrent chemotherapy with reirradiation is expected. Our results are subject </span></span><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">to limitations from the retrospective nature of the analysis, the relatively small number, and improper selection of patients. </span></span></span></span></span></span></span></span> |
| first_indexed | 2024-12-18T11:16:27Z |
| format | Article |
| id | doaj.art-70e2b3e59ddc46fbba9998c32977f022 |
| institution | Directory Open Access Journal |
| issn | 2357-0687 2357-0695 |
| language | English |
| last_indexed | 2024-12-18T11:16:27Z |
| publishDate | 2016-06-01 |
| publisher | Kasr Al-Ainy Center of Clinical Oncology and Nuclear Medicine |
| record_format | Article |
| series | Research in Oncology |
| spelling | doaj.art-70e2b3e59ddc46fbba9998c32977f0222022-12-21T21:09:55ZengKasr Al-Ainy Center of Clinical Oncology and Nuclear MedicineResearch in Oncology2357-06872357-06952016-06-011212910.21608/resoncol.2016.587587A Retrospective Study of Reirradiation for Patients with Locoregional Recurrent Head and Neck Cancer: A Single-Institution ExperienceDina Salem0Ahmed Essa1Azza Adel2Ahmed Refaa3Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, EgyptClinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, EgyptClinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, EgyptClinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt<span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">Aim: To assess the efficacy of reirradiation in locoregionally recurrent head and neck cancer (HNC) and </span></span><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">to describe results in our center in relation to other published data among similar group of patients. </span></span><br /> <span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">Methods: <span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">The medical records of 28 patients with HNC who received reirradiation with or without chemotherapy for loco-regional recurrence between 2005 and 2013 were reviewed. They were evaluated </span></span><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">for; toxicity profile, overall survival (OS) and progression free survival (PFS). </span></span></span></span><br /> <span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">Results: <span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">The median reirradiation dose was 50 Gy (range 40-60 Gy) and median radiation cumulative dose was 119 (range 113 -120). An overall response rate was seen in 36% of patients with only 3 patients showed complete response. The median OS was 9 months with 1-and 2-year survival rates being 34.1% </span></span><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">and 10.6%. The OS and PFS were significantly better in patients who were treated with chemotherapy </span></span><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">concomitant with radiation and received higher radiation dose. Grade 3 mucositis and skin reactions were seen in 24 % and 14% of patients, respectively. Conclusion: <span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">Reirradiation appears to be feasible in patients with recurrent HNC treated previously with </span></span><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">radiation. The benefit of concurrent chemotherapy with reirradiation is expected. Our results are subject </span></span><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">to limitations from the retrospective nature of the analysis, the relatively small number, and improper selection of patients. </span></span></span></span></span></span></span></span>https://resoncol.journals.ekb.eg/article_587_c9dc1a19a6306d4d48666d1f41703538.pdfreirradiationrecurrent head and neck cancerchemoradiotherapy |
| spellingShingle | Dina Salem Ahmed Essa Azza Adel Ahmed Refaa A Retrospective Study of Reirradiation for Patients with Locoregional Recurrent Head and Neck Cancer: A Single-Institution Experience Research in Oncology reirradiation recurrent head and neck cancer chemoradiotherapy |
| title | A Retrospective Study of Reirradiation for Patients with Locoregional Recurrent Head and Neck Cancer: A Single-Institution Experience |
| title_full | A Retrospective Study of Reirradiation for Patients with Locoregional Recurrent Head and Neck Cancer: A Single-Institution Experience |
| title_fullStr | A Retrospective Study of Reirradiation for Patients with Locoregional Recurrent Head and Neck Cancer: A Single-Institution Experience |
| title_full_unstemmed | A Retrospective Study of Reirradiation for Patients with Locoregional Recurrent Head and Neck Cancer: A Single-Institution Experience |
| title_short | A Retrospective Study of Reirradiation for Patients with Locoregional Recurrent Head and Neck Cancer: A Single-Institution Experience |
| title_sort | retrospective study of reirradiation for patients with locoregional recurrent head and neck cancer a single institution experience |
| topic | reirradiation recurrent head and neck cancer chemoradiotherapy |
| url | https://resoncol.journals.ekb.eg/article_587_c9dc1a19a6306d4d48666d1f41703538.pdf |
| work_keys_str_mv | AT dinasalem aretrospectivestudyofreirradiationforpatientswithlocoregionalrecurrentheadandneckcancerasingleinstitutionexperience AT ahmedessa aretrospectivestudyofreirradiationforpatientswithlocoregionalrecurrentheadandneckcancerasingleinstitutionexperience AT azzaadel aretrospectivestudyofreirradiationforpatientswithlocoregionalrecurrentheadandneckcancerasingleinstitutionexperience AT ahmedrefaa aretrospectivestudyofreirradiationforpatientswithlocoregionalrecurrentheadandneckcancerasingleinstitutionexperience AT dinasalem retrospectivestudyofreirradiationforpatientswithlocoregionalrecurrentheadandneckcancerasingleinstitutionexperience AT ahmedessa retrospectivestudyofreirradiationforpatientswithlocoregionalrecurrentheadandneckcancerasingleinstitutionexperience AT azzaadel retrospectivestudyofreirradiationforpatientswithlocoregionalrecurrentheadandneckcancerasingleinstitutionexperience AT ahmedrefaa retrospectivestudyofreirradiationforpatientswithlocoregionalrecurrentheadandneckcancerasingleinstitutionexperience |